Abstract
The review by Butler et al. (1) is a comprehensive look at pipeline antibacterial agents for WHO priority pathogens. It is reassuring that many innovative companies are endeavoring to ensure that clinicians will have options to treat carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa (CRPA), and Acinetobacter baumannii (CRAB). But, what about the other critical priority pathogens, the third-generation cephalosporin (3GC)-resistant Enterobacterales (2)? This group of resistant pathogens often seems to go overlooked, and in this review, was not included in Tables 3 or 4 or acknowledged in the Conclusion. Yet, they are leading causes of antimicrobial resistance (AMR)-attributed deaths globally (3).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
